U.S. Energy Boom Ke...
Health Care: Drugs
Transition Therapeutics Inc. (TTHI: NASDAQ)
$3.06 0.03 | 0.99%
05/23/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| TTHI | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 588.10 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 42.25 | 62.77 | -23.29 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | -100.00 | -1.00 | 0.00 |
| Net Income | -100.00 | -0.37 | 0.00 |
| EPS | -100.00 | -0.44 | 0.00 |
Earnings for TTHI:
| EBITDA | -10.00 |
| REVENUE | 0.00 |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (06/13) | FY (06/14) | |
|---|---|---|---|---|
| Average Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Number of Analysts | 0 | 0 | 0 | 0 |
| High Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Low Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Prior Year | $-0.10 | $0.29 | $-0.49 | $n.a. |
| Growth Rate (Year over Year) | n.a.% | n.a.% | n.a.% | n.a.% |
Portfolios with TTHI
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- UserThe 1000 Club
- UserBiotech for Obama Presidency
- ContributorStockerblog.com Canadian Li...
- UserPhels
Latest TTHI Headlines from TheStreet
- 5 Stocks Under $5 Making Big Moves 09.20.12 | 02:09 pm
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 5 Stocks With Huge Insider Buying 12.01.11 | 06:12 am
- Transition Therapeutics Inc. Stock Downgraded (TTHI) 05.23.11 | 08:05 am
- Transition Stock Gaps Up On Today's Open (TTHI) 03.21.11 | 09:03 am
- Transition Therapeutics Inc.: News Release 02.22.11 | 11:02 am
- Transition Stock Soars Higher (TTHI) 02.22.11 | 10:02 am
- Transition Therapeutics Inc. Stock Upgraded By TheStreet Ratings (TTHI) 02.09.11 | 05:02 pm
- Transition Therapeutics Announces Second Quarter Fiscal 2011 Financial Results 02.07.11 | 04:02 pm
- Transition Therapeutics To Hold Conference Call On Second Quarter Fiscal 2011 Financial Results On Monday, February 7th, At 4:30 P.M. EST 02.04.11 | 01:02 pm
Press Releases for TTHI
- Transition Therapeutics To Hold Conference Call On Third Quarter Fiscal 2013 Financial Results On Tuesday, May 7th, At 4:30 P.M. EST - PR Newswire 05.06.13 | 12:05 pm
- Transition Therapeutics Announces Results Of Clinical Study Of Type 2 Diabetes Drug Candidate TT-401 - PR Newswire 04.30.13 | 06:04 am
- Transition Therapeutics To Hold Conference Call On Second Quarter Fiscal 2013 Financial Results On Thursday, February 7th, At 4:30 P.M. EST - PR Newswire 02.04.13 | 12:02 pm
- Transition Therapeutics Announces Enrollment Of The First Patient In Phase 2 Study Of ELND005 (Scyllo-inositol) For The Treatment Of Agitation/Aggression In Patients With Alzheimer's Disease - PR Newswire 11.28.12 | 08:11 am
- Transition Therapeutics To Hold Conference Call On First Quarter Fiscal 2013 Financial Results On Thursday, November 8th, At 4:30 P.M. EST - PR Newswire 11.05.12 | 04:11 pm
- Transition Therapeutics To Hold Conference Call On Full Year Fiscal 2012 Financial Results On Thursday, September 13th, At 4:30 P.M. EST - PR Newswire 09.11.12 | 04:09 pm
- Transition Therapeutics Announces Dosing Of First Patient In Phase 2 Clinical Study Of ELND005 In Bipolar Disorder - PR Newswire 08.30.12 | 07:08 am
- Transition Therapeutics To Present At The Canaccord Genuity Annual Growth Conference - PR Newswire 08.13.12 | 04:08 pm
- LifeSci Advisors Announces Investment Opinion On Transition Therapeutics, Inc. - Business Wire 06.16.11 | 09:06 am
- Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study And Plans For Phase 3 For ELND005 (Scyllo-inositol ) - Business Wire 08.09.10 | 04:08 pm
Partner Headlines for TTHI
- Transition Therapeutics To Trade Higher Into Upcoming Trial Results For Diabetes Drug - Seeking Alpha 01.28.13 | 09:01 am
- Elan Starts Phase II ELND005 Study - Analyst Blog - NASDAQ 09.06.12 | 08:09 pm
- Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting - Benzinga 07.15.11 | 04:07 pm
- Morning Market Losers - Benzinga 05.31.11 | 10:05 am
- Morning Market Movers (FONR, TTHI, GFN, CEBK) - Benzinga 02.22.11 | 09:02 am
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- Elan to Move ELND005 to Phase III - Analyst Blog - Zacks 08.16.10 | 04:08 pm
